Hot Features
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumat... Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.82 | -12.0211360634 | 15.14 | 15.2375 | 13 | 626367 | 14.10972258 | CS |
| 4 | -2.66 | -16.6458072591 | 15.98 | 18.28 | 13 | 847246 | 15.22841138 | CS |
| 12 | -0.71 | -5.06058446187 | 14.03 | 19.7 | 11.7 | 1056973 | 15.02966901 | CS |
| 26 | 4.89 | 58.0071174377 | 8.43 | 19.7 | 7.91 | 1394687 | 13.46690064 | CS |
| 52 | 13.0923 | 5749.80237154 | 0.2277 | 49.95 | 0.1813 | 5518900 | 3.29526593 | CS |
| 156 | 8.47 | 174.639175258 | 4.85 | 49.95 | 0.1311 | 2249056 | 2.87381993 | CS |
| 260 | -6.79 | -33.76429637 | 20.11 | 49.95 | 0.1311 | 1397739 | 3.08341658 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.